secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001493152-23-009599
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon reports 2022 net loss of $35.9M ($5.03/share); cash $38.9M funds into 2025
--------------------------------------------------------------------------------

- Net loss $35.9M vs $20.8M in 2021; operating expenses up 18% to $25.4M.
- Non-cash impairment charge of $13.4M on IPR&D asset; $4.5M interest from preferred stock redemption.
- Cash $38.9M at year-end; expects to fund operations into 2025.
- OVATION 2 study fully enrolled; Phase 1/2 with bevacizumab opened.
- PLACCINE NHP data shows comparable protection to mRNA; stability >9 months at 4°C.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315223009599/0001493152-23-009599-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315223009599/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-009599

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer